Valuation: Capricor Therapeutics, Inc.

Market Cap 1.34B 1.18B 1.08B 1.01B 1.91B 128B 1.94B 12.96B 5.04B 62.91B 5.05B 4.94B 217B P/E 2026 *
-39.2x
P/E 2027 * -35.5x
Enterprise Value 1.34B 1.18B 1.08B 1.01B 1.91B 128B 1.94B 12.96B 5.04B 62.91B 5.05B 4.94B 217B EV / Sales 2026 *
11.4x
EV / Sales 2027 * 11x
Free-Float
90.53%
Yield 2026 *
-
Yield 2027 * -
1 day+0.61%
1 week-12.22%
Current month-3.61%
1 month-16.03%
3 months-27.72%
6 months-18.01%
Current year-19.58%
1 week 22.53
Extreme 22.53
27.05
1 month 22.53
Extreme 22.53
30.93
Current year 21.06
Extreme 21.0601
36.82
1 year 4.3
Extreme 4.3
40.37
3 years 2.68
Extreme 2.68
40.37
5 years 2.56
Extreme 2.56
40.37
10 years 0.88
Extreme 0.88
47.9
Manager TitleAgeSince
Chief Executive Officer 62 20/11/2013
Director of Finance/CFO 40 01/01/2018
Chief Tech/Sci/R&D Officer - 13/05/2025
Director TitleAgeSince
Chairman 70 01/11/2013
Director/Board Member 68 20/11/2013
Director/Board Member 79 20/11/2013
Date Insider Type Main position Quantity % Market Cap.
06-25Fiscal year

Chief Financial Officer

72,300 0.1248%
06-25Fiscal year

General Counsel

72,300 0.1248%
06-24Fiscal year

General Counsel

1,200 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
+0.61%-12.22%+126.44%+393.83% 1.34B
+0.68%+5.92%+80.45%+137.78% 59.1B
+2.32%+5.03%+75.51%+94.88% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 19.69B
-0.29%+9.78%+44.62%-27.94% 17.56B
0.00%+20.78%+178.93%+360.74% 16.22B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 14.84B
Average +2.64%+5.35%+61.82%+175.35% 24.68B
Weighted average by Cap. +2.45%+6.31%+59.42%+139.19%

Financials

2026 *2027 *
Net sales 118M 103M 94.86M 88.42M 168M 11.24B 170M 1.14B 443M 5.53B 443M 434M 19.04B 122M 107M 98.28M 91.61M 174M 11.65B 176M 1.18B 459M 5.73B 459M 449M 19.73B
Net income -28.4M -24.83M -22.82M -21.27M -40.34M -2.7B -40.96M -274M -106M -1.33B -107M -104M -4.58B -48.17M -42.11M -38.7M -36.07M -68.42M -4.59B -69.45M -465M -181M -2.25B -181M -177M -7.77B
Net Debt - -
Logo Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
Employees
231
Date Price Change Volume
02/07/26 $23.21 +0.61% 1,641,256
01/07/26 $23.07 -4.19% 1,807,652
30/06/26 $24.08 +1.18% 1,858,849
29/06/26 $23.80 -9.98% 3,243,527
26/06/26 $26.44 -13.03% 5,489,477
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
23.21USD
Average target price
53.60USD
Spread / Average Target
+130.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPR Stock